Alkem Laboratories Limited (ALKEM) Gross Profit 2022–TTM

Name: Alkem Laboratories Limited (ALKEM) gross profit history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Alkem Laboratories Limited annual gross profit for fiscal TTM was ₹99.6 billion, an increase of 6.7% from ₹93.3 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

ALKEM Annual Gross Profit

Gross Profit (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Gross Profit	₹99.6B	₹93.3B	₹79.5B	₹74.1B	₹64.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALKEM Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Gross Profit	₹25.4B	₹23.6B	₹24.6B	₹26.0B	₹22.0B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

MANKIND Gross Profit — Mankind Pharma Limited
LUPIN Gross Profit — Lupin Limited
4506 Gross Profit — Sumitomo Pharma Co., Ltd.
GLENMARK Gross Profit — Glenmark Pharmaceuticals Limited
ABBOTINDIA Gross Profit — Abbott India Limited
GLAND Gross Profit — Gland Pharma Limited

More ALKEM metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All ALKEM financial statements → Interactive ALKEM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.